Peptide-Based Gastrointestinal
Disorders Therapeutics Market Regional Analysis
North America Peptide-Based
Gastrointestinal Disorders Therapeutics Market is expected to exhibit good
growth over the forecast period, owing to presence of major players and
adoption of strategies such as mergers and collaborations by them for novel
peptide-based therapeutics. For instance, in February 2018, Cipher
Pharmaceuticals Inc. acquired exclusive Canadian rights of the U.S. Food and
Drug Administration approved drug Trulance (plecanatide) from Synergy
Pharmaceuticals Inc. After the acquisition, Cipher Pharmaceuticals Inc. will
develop, market, distribute, and sell Trulance (plecanatide) in the Canadian
Market.
Asia Pacific peptide-based
gastrointestinal disorders therapeutics market is expected to exhibit
significant growth over the forecast period, owing to increasing investments
made by players in the region to receive approval of novel peptide-based
therapeutics. For instance, in 2014, Ironwood Pharmaceuticals, Inc. received
US$ 15 million from Astellas Pharma Inc., a Japan-based pharmaceutical company,
for initiating Phase III clinical trial of Linzess (linaclotide) in Japan, and
receive its approval from Japanese Ministry of Health, Labor, and Welfare in
2016. Ironwood Pharmaceuticals, Inc. and Astellas Pharma Inc. were under
strategic partnership since 2009 for developing and commercializing linaclotide
in Japan.
Peptides are short chains of
amino acid monomers linked by peptide (amide) bonds. Peptide-based
gastrointestinal (GIT) disorders therapeutics are drugs that are used for the
treatment of various GIT disorders such as short bowel syndrome, chronic
constipation, and irritable bowel syndrome. In the recent past, some peptide-based
therapeutics such as Trulance, Linaclotide, and Teduglutide received approval
for the treatment of GIT disorders.
* The sample copy includes:
Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report
Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2028
Trulance is a guanylate cyclase-C
agonist indicated for the treatment of chronic idiopathic constipation in
adults. Linaclotide is a 14 amino acid peptide that acts as an agonist of
guanylate cyclase C receptors in the intestine. It is a minimally absorbed
agonist of guanylate cyclase C receptors in the intestine and is used for the
treatment of chronic constipation and irritable bowel syndrome. Teduglutide is
a new recombinant analogue for glucagon-like peptide (GLP) -2, a natural
occurring peptide, which is secreted primarily by the lower gastrointestinal
tract.
Peptide-Based Gastrointestinal
Disorders Therapeutics Market Dynamics
Frequent approval and launch of
novel peptide-based gastrointestinal disorders therapeutics in key regions is
expected to drive the global peptide-based gastrointestinal disorders
therapeutics market growth over the forecast period.
For instance, in 2017, Synergy
Pharmaceuticals Inc. received the U.S. Food and Drug Administration (FDA)
approval for its new drug TRULANCE (plecanatide) 3 mg tablet. This drug is
indicated for the treatment of irritable bowel syndrome with constipation
(IBS-C) in adults.
In 2012, Ironwood
Pharmaceuticals, Inc. and Forest Laboratories, Inc. received the U.S. Food and
Drug Administration approval for its drug called Linzess (linaclotide). Linzess
(linaclotide) is a guanylate cyclase-C agonist used for the treatment of adults
suffering from irritable bowel syndrome with constipation (IBS-C) and chronic
idiopathic constipation (CIC).
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/peptide-based-gastrointestinal-disorders-therapeutics-market-2028
In 2016, Ironwood
Pharmaceuticals, Inc.’s partner, Astellas Pharma Inc., received marketing
approval from the Japanese Ministry of Health, Labor, and Welfare for Linzess
(linaclotide), and in 2017, Astellas Pharma Inc. launched Linzess (linaclotide)
in Japan.
In 2012, NPS Pharmaceuticals,
Inc. received approval from the U.S. Food and Drug Administration (FDA) for its
drug Gattex (Teduglutide (rDNA origin)). Gattex 0.05 mg/kg/d injection is a
new, recombinant analog of human glucagon-like peptide 2, a protein involved in
the rehabilitation of the intestinal lining. It is indicated for the treatment
of adult patients with short bowel syndrome (SBS) who are dependent on
parenteral support. Sucg frequent approval is expected to cather peptide-based
gastrointestinal disorders therapeutics market growth in near future.
Furthermore, increasing
prevalence of gastrointestinal disorders is expected to rise the demand for
peptide-based drugs, which will in turn drive the global peptide-based
gastrointestinal disorders therapeutics market growth. For instance, according
to the data published by the International Foundation for Functional
Gastrointestinal Disorder in 2016, irritable bowel syndrome (IBS) is the most
common functional gastrointestinal (GI) disorder and globally, around 10-15% of
the population suffers from IBS.
Peptide-Based Gastrointestinal
Disorders Therapeutics Market Key Players
Key players operating in the
global peptide-based gastrointestinal disorders therapeutics market include
Ironwood Pharmaceuticals, Inc., NPS Pharmaceuticals, Inc., Synergy
Pharmaceuticals Inc., Astellas Pharma Inc., Allergan plc., and Cipher
Pharmaceuticals Inc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2028
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment